The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study
Authors:
- Tomoka NishimuraTNTomoka Nishimura
- Eiki IchiharaEIEiki Ichihara
- Toshihide YokoyamaTYToshihide Yokoyama
- Koji InoueKIKoji Inoue
- Tomoki TamuraTTTomoki Tamura
- Ken SatoKSKen Sato
- Naohiro OdaNONaohiro Oda
- Hirohisa KanoHKHirohisa Kano
- Daizo KishinoDKDaizo Kishino
- Haruyuki KawaiHKHaruyuki Kawai
- Masaaki InoueMIMasaaki Inoue
- Nobuaki OchiNONobuaki Ochi
Open Access
Abstract
Objectives: Combined immune checkpoint inhibitor (ICI) therapy and chemotherapy has become the standard treatment for advanced non-small-cell lung cancer (NSCLC). Pleural effusion (PE) is associated with poor outcomes among patients with NSCLC undergoing chemotherapy. However, minimal data exists on PE for patients undergoing combined ICI and chemotherapy. Therefore, we investigated how PE affects survival outcomes in patients with NSCLC undergoing this combined therapy. Methods: We identified patients with advanced NSCLC undergoing chemotherapy and ICI therapy from the Okayama Lung Cancer Study Group–Immune Chemotherapy Database (OLCSG–ICD) between December 2018 and December 2020; the OLCSG–ICD includes the clinical data of patients with advanced NSCLC from 13 institutions. Then, we analyzed the treatment outcomes based on the presence of PE. Results: We identified 478 patients who underwent combined ICI therapy and chemotherapy; 357 patients did not have PE, and 121 patients did have PE. Patients with PE had significantly shorter progression-free survival (PFS) and overall survival (OS) than those without PE (median PFS: 6.2 months versus 9.1 months; p < 0.001; median OS: 16.4 months versus 27.7 months; p < 0.001). The negative effect of PE differed based on the patient’s programmed cell death-ligand 1 (PD-L1) expression status; with the effect being more evident in patients with high PD-L1 expression. In addition, PFS and OS did not differ between patients who did and did not undergo bevacizumab treatment; thus, bevacizumab-containing regimens did not improve the survival outcomes for patients with PE. Conclusion: PE is associated with poor outcomes among patients with NSCLC undergoing combined ICI therapy and chemotherapy.Keywords
This publication has 27 references indexed in Scilit:
- Systematic review and meta‐analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusionsPhysiological Reports, 2016
- A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013ALung Cancer, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Prognostic Impact of Minimal Pleural Effusion in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2014
- Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusionCancer Chemotherapy and Pharmacology, 2012
- Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2012
- VEGF as a Mediator of Tumor-Associated ImmunodeficiencyImmunologic Research, 2001
- Malignant Pleural Effusion: Prognostic Factors for Survival and Response to Chemical Pleurodesis in a Series of 120 CasesRespiration, 1998